Introduction
Septicemiais frequently associated with intravascular coagulation and secondary organ failure, such as acute lung injury (1) (2) (3) . Infusion of endotoxin (lipopolysaccharide [LPS]) into animals has been shown to cause an activation of the coagulation cascade and to cause acute lung injury characterized by pulmonary hypertension, pulmonary endothelial injury, increased pulmonary vascular permeability, and pulmonary edema (4) (5) (6) (7) (8) . Serine proteases, such as thrombin, plasmin, or plasma kallikrein, generated during activation of the coagulation cascade have been shown to activate polymorphonuclear leukocytes (PMN) as well as to directly increase pulmonary vascular permeability (9) (10) (11) (12) . Thus, these proteases are thought to play a major role in the pathophysiology of LPS-induced acute lung injury. The response of thrombin infusion in animals resembles that seen after LPS administration in several respects, including pulmonary hypertension and increased pulmonary vascular permeability (10) . The direct effects of thrombin in vitro include increases in endothelial permeability (13) , vascular smooth muscle contraction (14) , activation of multiple PMN functions (15) , and thromboxane generation from various cells (16) (17) (18) . In vivo, the thrombininduced cleavage of fibrinogen to form soluble fibrin, which subsequently polymerizes to form fibrin clots, may also be a causative factor in LPS-induced acute lung injury. Soluble fibrin causes pulmonary hypertension in isolated perfused rabbit lungs (19) . In addition, thrombin may induce the release of tissue Plasminogen activator from the endothelial cells and thereby activate plasmin (20) . Fibrin degradation products (FDP) generated by plasmin are noxious agents in the lung and may increase vascular permeability (21) . Plasmin may also lead to complement activation resulting in PMN Chemotaxis (22) . The sum of these actions suggests a prominent role of thrombin in the pathogenesis of LPS-induced acute lung injury.
In this study, we used the thrombinspecific inhibitor, recombinant hirudin, to investigate the role of thrombin in a porcine model of LPS-induced acute lung injury. Hirudin, the anticoagulant from the medical leech, is a single-chain Polypeptide composed of 65 amino acid residues with a MT of 7,000 (23) . Recently, recombinant hirudin (r-hirudin) has become available (24) . r-Hirudin has the same inhibitory properties as the natural protein from the leech (25, 26) . Hirudin reacts with thrombin in an equimolar ratio to form an enzyme-inhibitor complex that blocks all the proteolytic activity of thrombin (27, 28) . In this respect, hirudin functions differently from other therapeutic anticoagulants such as heparin. Heparin, the antithrombin III (AT III) cofactor, accelerates the reaction of AT III with thrombin and other clotting factors (29) . Thus, the anticoagulant effectiveness of heparin depends on the concentration of AT III in plasma, which is low in cases of septic shock (30, 31) .
The objectives of this study were (1) to examine whether hirudin administration would inhibit the action of throm- bin generated during LPS infusion, and (2) to determine the effect of hirudin on acute lung injury following LPS infusion.
Methods

Animals
Anesthetized weaned miniature pigs of either sex (Minipig; Medical Service GmbH, Munich, FRG), weighing 18 to 23 kg, were used. The animals were fasted overnight, except for unlimited access to water. Only animals without signs of infection and with a baseline body temperature below 38.6° C, Hb above 7.0 g/ 100 ml, WBC 5,000 to 18,000/mm 3 , and lung compliance/kg body weight greater than 1 were included. All animal procedures were approved by the Tierschutzreferat, Regierung von Oberbayern. 
Anesthesia and Surgical Procedures
Experimental Protocol
After baseline measurements, 36 animals received a continuous infusion of 10 u.g/kg/h of Salmonella abortus equi endotoxin (LPS, batch M6-N1 TEN, 5 mg/ml, kindly provided by Dr. C. Galanos, Max-Planck Institut für Immunologie, Freiburg i.Br., FRG). These animals were randomly assigned into two groups: 18 animals (with hirudin) received a pretreatment of 1,000 U/kg of recombinant hirudin (batch: rBH5-7001/2, specific activity 11,114 U/mg; Plantorgan, Bad Zwischenahn, FRG), followed by a continuous infusion over 6 h of 500 U/kg/h given simultaneously with the infusion of LPS. Another 18 animals (w/o hirudin) did not receive hirudin but received a continuous infusion over 6 h of LPS and placebo. All treatments were given as an equal volume of 0.3 ml/kg/h. In addition, 6 control animals received not LPS but saline (n = 3) or r-hirudin (n = 3) according to the protocol of the corresponding LPS groups. Hemodynamic measurements and blood gas analysis were performed hourly. EDTAanticoagulated or heparinized blood samples were drawn every hour and citrated (K10 with 3.8% citrate) blood samples every 2 h. The blood was centrifuged at 1,500 x g for 10 min and the plasma aliquoted and kept at -80° C until measurement. After the end of the 6-h Observation period, the surviving animals were sacrificed by the injection of 2.0 g embutramide + 0.5 g mebezonium-jodine + 0.05 g tetracainhydrochloride (=10 ml of T 61; Hoechst Pharmaceuticals, Munich, FRG). recently described (34,35) . r-Hirudin in plasma was measured on citrated plasma samples using an ELISA modified for porcine plasma (36).
Physiologie and Biochemical Methods
Statistical Analysis
We used a factorial analysis of variance to analyze the effect of hirudin administration on the parameters that we measured (37). We employed the paired Student's t test to make comparisons within groups. Differences were as in the presence of hirudin the increase in soluble fibrin was reduced to 236 (171 to 300) ng/ml (p = 0.0002; figure 2 ). Antiplasmin activities in plasma decreased gradually during LPS infusion to approximately 70% of baseline by the last measurement; no significant effect of hirudin was detected ( 
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2 h 4 h LAST responded similarly initially to LPS in the absence and in the presence of hirudin. PVR increased to approximately three times baseline level by 1 h and then decreased to approximately 1.5 x baseline at 2 h in the absence and in the presence of hirudin. Thereafter, PVR increased again, reaching 32 (27 to 37) kdyn x s x cm" 5 x kg (last measurement) in the absence of hirudin. This increase was significantly reduced to 20 (15 to 25) kdyn x s x cm" 5 x kg in the presence of hirudin (p = 0.0015, figure 3 ). The LPS-induced changes in lung dynamic compliance (Cixlyn) and in alveolararterial oxygen difference (AaPo2) were similar in the absence and in the presence of hirudin; hirudin had no significant effect on either parameter. AaPo2 increased to approximately two times baseline by the last measurement; Cixlyn decreased to approximately 50% of baseline by the last measurement (table 2) . The extravascular lung water increased from 10.1 (9.4 to 10.7) ml/kg at baseline to 15.4 (13.2 to 17.6) ml/kg (last measurement) in the absence of hirudin. In the presence of hirudin, the increase in EVLW was significantly reduced to 12.2 (10.0 to 14.4) ml/kg (p = 0.0299, figure  4) . We calculated the total intravascular protein as the product of plasma volume times total protein concentration in serum, corrected for body weight. The IVP was 2.9 (2.7 to 3.1) g/kg at baseline. Hirudin reduced the loss of IVP during 4 h of LPS infusion from -0.76 (-0.98 to -0.54) g/kg to -0.49 (-0.72 to -0.26) g/kg. This effect was marginally significant (p = 0.0448, figure 5 ). In saline or hirudin control animals, no significant changes in Pä, CO, PVR, Cixlyn, AaPo2, EVLW, or IVP were noted during the Observation period.
Hematologic Data
The peripheral leukocyte count (WBC) in the absence and in the presence of hirudin plummeted within 2 h after the Start of the LPS infusion and remained low. The leukopenic response was not significantly different in the absence or presence of hirudin. However, since there was a significant difference in baseline WBC counts in the absence and in the presence of hirudin, interpretation of these results is limited (table 3) . Circulating platelets decreased similarly in the absence and in the presence of hirudin to approximately 50% of baseline at the last measurement; hirudin had no significant effect (table 3) animals did not show significant changes in WBC or platelets.
PMN Activation
We measured the concentrations of the cytosolic leukocyte neutral Proteinase inhibitor (LNPI) and of LNPI-bound lysosomal PMN elastase in plasma to assess PMN activation and lysosomal discharge during LPS infusion. The LNPI concentration was 150 (138 to 162) ng/ml at baseline and increased to approximately three times baseline level during LPS infusion. LNPI by the last measurement was 450 (367 to 552) ng/ml in the absence of hirudin and 395 (320 to 487) ng/ml in the presence of hirudin; this difference was not significant (p = 0.0798). PMN elastase concentrations in plasma increased from values below the detection limit (< 1 ng/ml) at baseline to 37 (27 to 47) ng/ml in the absence of hirudin, whereas in the presence of hirudin this increase was significantly reduced to 23 (13 to 33) ng/ml (p = 0.0137; figure 6 ). In saline and hirudin controls, the LNPI concentration in plasma did not change and the PMN elastase concentration in plasma was below the detection limit during the 6-h Observation period.
Mortality Rate
All control animals (n = 6) survived the 6-h Observation period. Of 36 animals given LPS, 5 died between 2 and 4 h after the Start of the LPS infusion. A total of 12 animals died between 4 and 6 h, resulting in an overall mortality rate of 17 of 36 (47%). In the absence of hirudin, the mortality rate was 10 of 18 (56%) and in the presence of hirudin 7 of 18 (39%), respectively. This difference was not statistically significant (Mantel-Haenszel test).
Discussion
The results of the present study show that hirudin reduces the consumption of plasma fibrinogen and the increase in soluble fibrin in plasma in a porcine model of endotoxemia. The administration of hirudin also attenuates the increase in pulmonary vascular resistance, the increase in extravascular lung water, and the loss of protein-rich fluid from the vasculature following LPS infusion. Furthermore, hirudin reduces the LPSinduced increase in PMN elastase concentration in plasma.
The LPS-induced consumption of coagulation factors in the present study was similar to that observed in septic patients (2, 30) . The decrease in plasma Prothrombin and plasma fibrinogen and the increase in soluble fibrin in plasma are evidence of the generation of thrombin. As expected, hirudin had no effect on the plasma Prothrombin levels but prevented the consumption of plasma fibrinogen and the increase in soluble fibrin in plasma; this indicates that hirudin ef fectively inhibits thrombin generated during LPS infusion. However, AT III in plasma decreased similarly in the absence and presence of hirudin. This may not be surprising, since the decrease in AT III during endotoxemia does not necessarily reflect intravascular coagulation (38). The consumption of AT III in endotoxemia may be more the result of unspecific proteolysis by, for example, PMN elastase (4). Furthermore, hirudin did not seem to have an inhibitory effect on the activation of plasmin since antiplasmin activities in plasma were not significantly dif ferent in the absence or presence of hirudin.
It is conceivable that the observed hirudin effects result from the Inhibition of thrombin by hirudin. Hirudin is a highly specific inhibitor of thrombin and does not inhibit other serine proteases such as trypsin, plasmin, factors IXa, Xa, and Xlla, or plasma and tissue kallikreins (26, 39) . The dose of hirudin we administered resulted in plasma levels in the ränge of 70 to 100 nmol/L, which equal 5 to 9 antithrombin units/ml. Since hirudin is a high-affinity inhibitor of thrombin that forms enzyme-inhibitor complexes in an equimolar ratio (25) , this dosage ensures sufficient molar inhibitor concentrations if the thrombin concentration in plasma during activation of the coagulation cascade is assumed to be approximately 1 to 2 U/ml (40) .
We determined the total intravascular protein as a product of the plasma volume and the plasma protein concentration to assess the loss of protein-rich fluid from the vasculature during LPS infusion. Hirudin reduced the loss of protein-rich fluid by approximately 36%, which suggests that thrombin inhibition by hirudin may reduce LPS-induced capillary leakage. Furthermore, hirudin attenuated the LPS-induced acute lung injury as evidenced by a smaller increase in PVR and in extravascular lung water. All animals showed the typical biphasic response in PVR to endotoxin (7, 8) . Hirudin inhibited the increase in the later phase, in agreement with previous studies using native hirudin from the leech in endotoxemic pigs (5) . Hirudin also blunted the increase in EVLW that occurred during LPS infusion. This may be due to the reduced pulmonary pressor response or to less increase in permeability of the lung vasculature to protein; the results of the present study do not allow us to discriminate between these two possibilities. Despite reduced EVLW increases in the presence of hirudin, AaPo2 decreased to the same degree in the absence and in the presence of hirudin; this suggests that pulmonary edema was not of major importance in the deterioration of pulmonary gas exchange. These findings are in accordance with observations in other animal models of LPS-induced acute lung injury (7, 41) and indicate that arterial hypoxemia following LPS infusion is primarily a consequence of ventilation/perfusion inequalities.
It may be exceedingly difficult to determine the separate and specific mechanisms of the observed attenuation of acute lung injury in the presence of hirudin. Less consumption of plasma fibrinogen and a smaller increase in the soluble fibrin in plasma in the presence of hirudin may be one explanation. In isolated perfused rabbit lungs, soluble fibrin causes vasoconstriction and pulmonary hypertension (19) . It is also conceivable, however, that less fibrin generation in the presence of hirudin resulted in less generation of fibrin degradation products (FDP). FDP released after the action of plasmin on fibrin are thought to contribute to the development of acute lung injury by increasing the permeability of the lung vasculature to protein (21, 42) . We have previously shown that the infusion of a fibrin-derived peptide into pigs causes an increase in EVLW (43) . However, there may be alternative explanations, other than inhibition of the proteolytic cleavage of fibrinogen by thrombin, for the observed hirudin effects. In this respect it is notable that in the absence of fibrinogen in isolated guinea pig lungs perfused with Ringer's albumin, hirudin also blocks the pulmonary pressure response and pulmonary edema formation after the injection of thrombin (44) . In this and other models of thrombin-induced acute lung injury, as well as in models of LPS-induced acute lung injury, the pulmonary hemodynamic response has been shown to be mediated in part by the generation of cyclo-oxygenase-derived metabolites such as thromboxane (8, 44, 45) . Thrombin is known to directly induce the in vitro generation of thromboxane from endothelial cells, vascular smooth muscle cells (16, 17) , and PMN leukocytes and lymphocytes (18) . Hirudin has been shown to abolish the thrombin-induced thromboxane generation from PMN leukocytes and lymphocytes in vitro (18) . Likewise, hirudin inhibited the thrombin-induced contraction of vascular smooth muscles of isolated rabbit aorta and dog coronary arteries (14) . Therefore it also seems possible that hirudin may block the direct cellular effects of thrombin that are independent of the proteolytic cleavage of the fibrinogen molecule.
In animal models of thrombin infusion, PMN leukocytes appeared to be important in mediating thrombin-induced acute lung injury since the response was attenuated by PMN depletion (9) . We observed a rapid and sustained decrease in the circulating leukocyte count following endotoxin infusion, but we did not detect a significant difference in leukopenia in the presence or absence of hirudin. One explanation may be that plasmin activation occurred similarly in the absence and in the presence of hirudin. Plasmin causes the cleavage of complement proteins and the formation of the complement-derived chemotactic peptides, C3a and C5a (22, 46) . On the other hand, the thrombin molecule itself is a weak chemotactic agent and induces PMN aggregation (47); this effect is blocked when thrombin is complexed with hirudin (15) . Although peripheral leukopenia does not seem to be affected by hirudin, we provide evidence that hirudin attenuated the lysosomal discharge of PMN leukocytes as determined by inhibitor-bound PMN elastase concentrations in plasma. Plasma levels of LNPI-bound PMN elastase were lower in the presence of hirudin than in the absence of hirudin. LNPI, an inhibitor of neutral proteinases, was recently isoiated and characterized from porcine PMN leukocytes (34) . The occurrence of this inhibitor and of the LNPI-PMN elastase complex in plasma has been identified as a marker of PMN leukocyte activation in porcine experimental septicemia (35) . The data therefore demonstrate that hirudin reduces endotoxin-induced increases in PMN elastase in plasma, suggesting thrombin activation is an important factor in PMN activation after LPS infusion.
In conclusion, our data substantiate the role of thrombin in mediating acute lung injury following LPS infusion in pigs. Possible mechanisms involve the generation of soluble fibrin and FDP, a direct effect of thrombin, and the activation of PMN leukocytes. Administration of hirudin, a highly selective thrombin inhibitor, prevented the LPS-induced intravascular coagulation and attenuated the LPS-induced acute lung injury.
